Mr. Neil Flanzraich
Chairman of the Board and Co-Founder
Mr. Flanzraich is the Chairman and Co-Founder of AgoneX Biopharmaceuticals, Inc. He is also the Executive Chairman of Cantex Pharmaceuticals, Inc., (https://cantex.com/) a biotech company developing novel therapies for cancer and inflammatory lung diseases. He is also the Executive Chairman of the Board of Directors of Alzheon, Inc., (https://alzheon.com/) a biotech company developing drugs for Alzheimer’s and other neurodegenerative conditions.
He was an early investor in Chipotle Mexican Grill, Inc. (CMG:NYSE), and served on its Board and as its Lead Independent Director for many years. He retired from Chipotle’s Board in May, 2022.
He was a member of the Board of Directors of Atrium European Real Estate Limited (VSE/Euronext:ATRS), until February 18, 2022 when it was merged into a larger company. He served as the Chairman of the Special Committee which negotiated the merger agreement, and led the outreach to Atrium’s shareholders in obtaining approval for the merger.
Mr. Flanzraich was the Lead Independent Director of Equity One, Inc. (EQY:NYSE) until its acquisition by Regency Centers Corp. (REG:NASDAQ).
Mr. Flanzraich has played leading roles in developing highly successful pharmaceutical companies. Mr. Flanzraich served as the Vice Chairman and President of Ivax Corporation (IVX:NYSE), an international pharmaceutical company, until it was sold to Teva Pharmaceutical Industries Ltd. (TEVA:NYSE) in 2006, for an enterprise value of $10 Billion. He was a senior Vice President, the General Counsel and a member of the Executive and Management Committees of Syntex Corporation (SYN:NYSE), until it was sold to Roche Holding AG for $5.3 Billion.
He was also the Chairman of North American Vaccine, Inc., and negotiated its sale to Baxter International, Inc. (BAX:NYSE).
Mr. Flanzraich was previously also a director of Continucare Corporation (CNU:NYSE); Javelin Pharmaceuticals, Inc. (JAV: AMEX); BELLUS Health Inc. (BLU:TSX); and Rae Systems, Inc. (RAE:AMEX). He was also a Director of Whitman Education Group, Inc. (WIX:AMEX) until it was sold to Career Education Corporation for $1B.
He has also consulted for various institutions concerning their pharma/biotech transactions and investments. He was the Chairman of the Life Sciences Legal Practice Group of Heller Ehrman White & McAuliffe, a 600-lawyer San Francisco-based law firm , with offices from Seattle to San Diego.
Mr. Flanzraich graduated from Harvard College (magna cum laude, Phi Beta Kappa) and from Harvard Law School (magna cum laude). Mr. Flanzraich was for years an Expert-In-Residence for an entrepreneurship program at Harvard Business School and Harvard Law School. He serves as a judge in the Harvard Innovation Labs President’s Innovation Challenge.
Mr. Flanzraich is married to a physician and they have two sons. He has written and published a series of Sci-fi novels: Geniuses®, Geniuses® II and Geniuses® III.
Mr. Wayne P. Yetter
Board of Directors Member
Wayne Yetter had a 30-year career in the pharmaceutical industry and held executive positions at Pfizer, Merck, Astra-Merck (now AstraZeneca) and Novartis. His roles included President and Chief Executive Officer of Novartis Pharmaceuticals Corporation, the US division of Novartis AG, Vice President, Marketing Operations (global) and Vice President, Far East and Pacific at Merck and founding Chief Executive Officer of Astra-Merck. He also served as Chief Operating Officer of IMS Health, a market research data company from 1999 until 2000, when he became Chairman and Chief Executive Officer of Synavant, Inc. (a Nasdaq listed spin-out of IMS) that was acquired by Dendrite International in 2003. Mr. Yetter then served as Chief Executive Officer of Verispan LLC, a Joint venture of McKesson and Quintiles and leading provider of healthcare information and marketing services to the pharmaceutical industry, from 2005 to 2008. Verispanwas acquired by SDI Health and later merged into IMS. Most recently, Mr. Yetter was Chairman of the Board of NuPathe Inc. that was acquired by TEVA in early 2014. He serves as a director of InfuSystem Holdings, Inc.(INFU), and Special Diversified Opportunities Inc. (SDOI) a shell company remaining after the sale of assets of Strategic Diagnostics. (SDIX). Previously he served as Chairman of Noven Pharmaceuticals, Chairman of Transkaryotic Therapies, and Lead Independent Director of Matria Healthcare (each of these companies was acquired). He served on the Executive Committee of PhRMA, the pharmaceutical industry association, from 1997-1999. Mr. Yetter holds a B.A. in Biology from Wilkes University and an M.B.A from Bryant University.
Cris Arnou, MSE, MBA,
Board of Directors Member, Co-Founder and CEO
Cris Arnou is AgoneX Biopharmaceuticals Inc. Co-Founder and CEO. As a migraine sufferer for more than 35 years he is determined and committed to implementing the migraine treatment and prevention throughout the U.S. via existing medical offices.
In the past, Mr. Arnou has worked for two start-up companies and knows what it takes to build a successful, prosperous business. Additionally, Cris spent 10 years working at Ford Motor Company covering different aspects of product development, marketing and product launch.
Cris holds Bachelor and Master Degrees in Engineering from the University of Michigan, Ann Arbor and an MBA from Wayne State University in Detroit. He is a veteran of the U.S. Army.
Randy Jones, JD
Board of Directors Member, Chief Legal Officer and Secretary
Randy Jones is Chief Legal Officer and Secretary for AgoneX Biopharmaceuticals Inc. He is also Principal of Solutions Business Group, which he founded in 2009 as a business services firm dedicated to assisting for-profit and non-profit businesses achieve stretch goals, resolve difficult challenges and navigate periods of change or transition. Prior to founding Solutions Business Group, Mr. Jones spent more than 20 years working for global corporations in a wide range of industries including pharmaceuticals, biotech, energy and chemicals. His distinguished career encompasses a variety of roles including engineer, in-house legal counsel and senior executive in charge of legal, human resources, corporate compliance and ethics. Mr. Jones also spent 6 years as General Counsel of TalecrisBiotherapeutics, a company that reached a $4.4B market cap. Mr. Jones holds a Bachelor of Chemical Engineering from the University of Delaware and a Juris Doctor from the University of Virginia.